Unknown

Dataset Information

0

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.


ABSTRACT: The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21. CD4+ and CD8+ T-cells were tested for antigen-specific proliferation by flow cytometry, and IFN-? production was tested by ELISA. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. We could detect antigen-specific IFN-? responses in 25% blood samples for NY-ESO-1 and 30% for survivin. NY-ESO-1-expanded T-cells recognized naturally processed and presented epitopes. NY-ESO-1 or survivin expression in glioma represents viable targets for anticancer-directed T-cells for the biological therapy of patients with glioma.

SUBMITTER: Liu Z 

PROVIDER: S-EPMC5799356 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma.

Liu Zhenjiang Z   Poiret Thomas T   Persson Oscar O   Meng Qingda Q   Rane Lalit L   Bartek Jiri J   Karbach Julia J   Altmannsberger Hans-Michael HM   Illies Christopher C   Luo Xiaohua X   Harvey-Peredo Inti I   Jäger Elke E   Dodoo Ernest E   Maeurer Markus M  

Cancer immunology, immunotherapy : CII 20171020 2


The prognosis for patients with glioblastoma is grim. Ex vivo expanded tumor-associated antigen (TAA)-reactive T-cells from patients with glioma may represent a viable source for anticancer-directed cellular therapies. Immunohistochemistry was used to test the survivin (n = 40 samples) and NY-ESO-1 (n = 38 samples) protein expression in tumor specimens. T-cells from peripheral blood were stimulated with TAAs (synthetic peptides) in IL-2 and IL-7, or using a combination of IL-2, IL-15 and IL-21.  ...[more]

Similar Datasets

| S-EPMC1570182 | biostudies-literature
| S-EPMC2629307 | biostudies-literature
| S-EPMC5844797 | biostudies-literature
| S-EPMC4015172 | biostudies-literature
| S-EPMC5806520 | biostudies-literature
| S-EPMC7394304 | biostudies-literature
| S-EPMC4485840 | biostudies-other
| S-EPMC6233129 | biostudies-literature
| S-EPMC3189057 | biostudies-literature
| S-EPMC4040020 | biostudies-literature